INmune Bio Inc (INMB)
Healthcare
Biotechnology
1.90 $
+5.7%
vs. previous close
Closing price · As of: 3. Aug 2026
Who owns INmune Bio Inc (INMB)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 83.2% of the shares are freely tradable; institutional investors hold 19.7%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
19.7%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
11.2%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
83.2%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
10.1%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
27Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 4.49 | 1,194,112 | -1.5 | 03/31/2026 |
| Vanguard Capital Management, LLC | 2.58 | 687,015 | +0.0 | 03/31/2026 |
| Geode Capital Management, LLC | 1.86 | 494,969 | +12.1 | 03/31/2026 |
| State Street Corp | 1.09 | 290,879 | -16.2 | 03/31/2026 |
| AQR Capital Management LLC | 1.02 | 270,317 | +1,217.4 | 03/31/2026 |
| UBS Group AG | 0.95 | 253,340 | +316.7 | 03/31/2026 |
| The Goldman Sachs Group Inc | 0.87 | 231,586 | +310.1 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Morn Total Stk Mkt Idx Investor | 1.84 | 490,268 | +0.0 | 06/30/2026 |
| Fidelity Small Cap Index | 0.87 | 231,535 | +9.5 | 05/31/2026 |
| Vanguard Institutional Extnd Mkt Idx Tr | 0.74 | 195,995 | +0.0 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.